Quick Answer
Burning Rock Biotech Ltd reported Cash and Equivalents of $519.85 million for fiscal year 2024.
Burning Rock Biotech Ltd Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $519.85M | -15.5% |
| 2023 | $615.10M | -32.1% |
| 2022 | $905.45M | -36.7% |
| 2021 | $1.43B | -24.5% |
| 2020 | $1.90B | +1911.3% |
| 2019 | $94.23M | +1.0% |
| 2018 | $93.34M | — |
- Burning Rock Biotech Ltd showed a decrease of -15.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2024 period, Burning Rock Biotech Ltd’s cash and equivalents has grown by 456.9% (from $93.34 million to $519.85 million).
- The most recent figure is from Burning Rock Biotech Ltd’s fiscal year 2024 report (Form 20-F), filed with the SEC on April 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: